Suertides A-C: selective antibacterial cyclic hexapeptides from Amycolatopsis sp. MST-135876v3.

Heather J Lacey, Rachel Chen, Daniel Vuong, Mark F Fisher, Ernest Lacey, Peter J Rutledge, Andrew M Piggott

Abstract read

In one paragraph

Article in The Journal of antibiotics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Sources and Metabolism of D-Amino Acids and Their Roles as Biomarkers in Kidney Disease: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Heather J LaceyMicrobial Screening Technologies, Sydney, NSW, 2164, Australia. hlac5959@uni.sydney.edu.au.ORCID 0000-0001-5332-8470

Rachel ChenMicrobial Screening Technologies, Sydney, NSW, 2164, Australia.

Daniel VuongMicrobial Screening Technologies, Sydney, NSW, 2164, Australia.

Mark F FisherSchool of Molecular and Life Sciences, Curtin University, Perth, WA, 6102, Australia.

Ernest LaceyMicrobial Screening Technologies, Sydney, NSW, 2164, Australia.ORCID 0000-0002-5387-2721

Peter J RutledgeSchool of Chemistry, The University of Sydney, Sydney, NSW, 2006, Australia.ORCID 0000-0002-0767-5196

Andrew M PiggottSchool of Natural Sciences, Macquarie University, Sydney, NSW, 2109, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amycolatopsis sp. MST-135876 was isolated from soil collected from the riverbank of El Pont de Suert, Catalonia, Spain. Cultivation of MST-135876 on a range of media led to the discovery of a previously unreported dichlorinated cyclic hexapeptide, suertide A (D-Ser, 5-Cl-D-Trp, 6-Cl-D-Trp, L-Ile, D-Val, D-Glu), featuring an unprecedented pair of adjacent 5/6-chlorotryptophan residues. Supplementing the growth medium with KBr resulted in production of the mono- and dibrominated analogues suertides B and C, respectively. Suertides A-C displayed selective activity against Bacillus subtilis (MIC 1.6 µg ml

Indexed as

AmycolatopsisMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsMicrobial Sensitivity TestsStaphylococcus aureusAnti-Bacterial Agents

Identifiers

PMID35882958

DOI10.1038/s41429-022-00544-4

PMCPMC9359914

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.